Adrin Dsouza

Building Kim - Personal Health Assistant

[Kim @just_askkim]

JUST IN: Gen Z’s daytime parties are getting a wellness makeover. Some events are swapping alcohol for run clubs, cold plunges and functional drinks, basically turning fitness and recovery into the social activity itself.

[Kim @just_askkim]

JUST IN: A new study suggests AI can pull much more heart-failure information from a standard ECG than doctors normally get from the test alone. In more than 8,000 patients, the AI score tracked with structural and functional heart problems seen on ultrasound.

[Adrin Dsouza @adrindsouza10]

@Owenfitzgerald alot happening in this image lol

[Adrin Dsouza @adrindsouza10]

@mindinpanic left for sure. posthog type of vibe lol

[Adrin Dsouza @adrindsouza10]

This is actually a pretty big deal. And let me explain why.

First, what even is heart failure with preserved ejection fraction?

It’s called HFpEF.

Basically, the heart can still squeeze out a normal or near-normal percentage of the blood inside it.

But it often doesn’t relax and fill normally. That raises pressure inside the heart and can leave people short of breath, exhausted, swollen, and unable to exercise normally.

Obesity is one of the major drivers of a common form of HFpEF.

Which brings us to semaglutide and tirzepatide.

Semaglutide is a GLP-1 receptor agonist.

Tirzepatide targets both GIP and GLP-1 receptors.

Most people still think of them mainly as weight-loss drugs.

But researchers started asking a much more interesting question:

If obesity is contributing to the heart failure itself, what happens if you aggressively treat the obesity?

And the results have been surprisingly strong.

In the STEP-HFpEF trial, researchers studied 529 people with obesity and HFpEF.

They gave one group semaglutide for 52 weeks.

The semaglutide group lost substantially more weight, but that wasn’t the only thing that changed.

They also reported better heart-failure symptoms and physical limitations.

And in the 6-minute walking test, people taking semaglutide improved by about 20 metres more than the placebo group.

Researchers then ran a similar trial in people who also had type 2 diabetes.

Again, semaglutide improved symptoms, physical limitations, weight, and exercise capacity compared with placebo.

Then came tirzepatide.

The SUMMIT trial included 731 people with obesity and HFpEF and followed them for a median of roughly two years.

Cardiovascular death or worsening heart failure happened in:

9.9% of the tirzepatide group

versus

15.3% of the placebo group.

That works out to about a 38% relative reduction in the combined endpoint.

But there’s an important detail.

The difference was mainly driven by fewer worsening heart-failure events.

Worsening heart failure occurred in:

8.0% with tirzepatide

versus

14.2% with placebo.

There were too few cardiovascular deaths to conclude that tirzepatide makes people with HFpEF live longer.

And now cardiology guidance is changing.

The 2026 American College of Cardiology HFpEF guidance says that in people with HFpEF and a BMI of 30 or higher, semaglutide or tirzepatide may be prescribed to improve health status and exercise function, and potentially reduce worsening heart-failure events.

That sentence would have sounded pretty wild a few years ago.

But there is an important catch.

This does not mean Ozempic or Zepbound suddenly cures heart failure.

These studies were specifically in people with obesity and HFpEF.

And we still don’t completely know how much of the benefit comes from losing a large amount of weight versus other effects on inflammation, blood volume, metabolism, kidney function, or the cardiovascular system itself.

There’s also the issue of preserving muscle during treatment, especially in older adults, because major weight loss can include loss of lean mass.

Exercise and adequate nutrition still matter.

And neither semaglutide nor tirzepatide currently has a specific U.S. FDA indication for treating HFpEF itself.

But I think the bigger story here is fascinating.

GLP-1-based drugs started as diabetes drugs.

Then they became weight-loss drugs.

Then cardiovascular-risk drugs.

Tirzepatide also became an approved treatment for certain people with obesity and moderate-to-severe obstructive sleep apnea.

And now these drugs are making their way directly into how cardiologists think about treating obesity-related heart failure.

So these are becoming much more than “weight-loss injections.”

We are watching this drug class expand far beyond diabetes and weight loss in real time.

[Kim @just_askkim]

JUST IN: GLP-1 drugs are moving further beyond weight loss. New heart-failure guidance now recommends semaglutide or tirzepatide for some people with obesity and heart failure with preserved ejection fraction.

[Adrin Dsouza @adrindsouza10]

@AnxiousHolly iPhone 6 deja vu

[Kim @just_askkim]

JUST IN: Microplastics were detected in 84% of patients having a major heart attack in a small new study, compared with 32% of people with healthy coronary arteries.

[Adrin Dsouza @adrindsouza10]

Creativity at its peak

[Adrin Dsouza @adrindsouza10]

Me checking X every morning.

[Adrin Dsouza @adrindsouza10]

modern book

[backup cat @abackupacc88]

Buying that iPhone to show the world what I'm reading

[Adrin Dsouza @adrindsouza10]

Does anyone use @Meta models for their products??

[Adrin Dsouza @adrindsouza10]

Agent to agent interactions are gonna be insane

[Adrin Dsouza @adrindsouza10]

funny how crypto wasn't their first choice lol

[Kalshi @Kalshi]

JUST IN: Venture capitalist says Pokémon cards would become the global currency if the world suffered an apocalypse

[Adrin Dsouza @adrindsouza10]

I remember perplexity doing this lol. Btw, where are they now???

[ChatGPT @ChatGPT]

Now everyone can put data to work.

We’re introducing a new Data agent in ChatGPT Work so you can turn your company’s data into answers, interactive dashboards, and action—just by asking.

Just add the Data Plugin in ChatGPT Work, connect to the data sources and context you already use, and start the conversation. https://t.co/EG1nQFZfEU